1.Safety and tolerability of Vardenafil.
National Journal of Andrology 2006;12(9):857-860
This paper reviewed the safety and tolerability of vardenafil in the treatment of erectile dysfunction (ED), including the general, cardiovascular and ocular safety. Results from clinical trials and practice experience demonstrated that vadenafil had good safety and tolerability, whether for general ED population or for difficult-to-treat ED patients, whether as short-term treatment or as long-term therapy.
Drug Tolerance
;
Erectile Dysfunction
;
drug therapy
;
Humans
;
Imidazoles
;
adverse effects
;
therapeutic use
;
Male
;
Middle Aged
;
Phosphodiesterase Inhibitors
;
adverse effects
;
therapeutic use
;
Piperazines
;
adverse effects
;
therapeutic use
;
Sulfones
;
adverse effects
;
therapeutic use
;
Treatment Outcome
;
Triazines
;
adverse effects
;
therapeutic use
;
Vardenafil Dihydrochloride
2.Treatment of erectile dysfunction after radical retropubic prostatectomy with PDE5 inhibitor.
National Journal of Andrology 2005;11(9):708-712
The rate of erectile dysfunction after radical retropubic prostatectomy is from 10% to 100%. The prevalence of erectile dysfunction after nerve-sparing radical prostatectomy is more than one third. In the patients who had undergone bilateral NS, 72% responded to sildenafil, 71.7% and 59.7% responded to 20 mg and 10 mg of vardenafil respectively. For all randomized patients who received tadalafil, the mean percentage of successful penetration attempts was 54% and the mean percentage of successful intercourse attempts was 41%. For the subgroup with evidence of postoperative tumescence these values were 69% and 52%, respectively. No head-to-head trials have been performed with sildenafil, vardenafil and tadalafil in treatment of erectile dysfunction after radical prostatectomy.
Carbolines
;
therapeutic use
;
Erectile Dysfunction
;
drug therapy
;
etiology
;
Humans
;
Imidazoles
;
therapeutic use
;
Male
;
Phosphodiesterase Inhibitors
;
therapeutic use
;
Piperazines
;
therapeutic use
;
Prostatectomy
;
adverse effects
;
Purines
;
therapeutic use
;
Sildenafil Citrate
;
Sulfones
;
therapeutic use
;
Tadalafil
;
Triazines
;
therapeutic use
;
Vardenafil Dihydrochloride
3.Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension.
Jun-ren ZHU ; Nai-sheng CAI ; Wei-hu FAN ; Ding-liang ZHU ; Ben HE ; Zong-gui WU ; Yuan-nan KE ; Jing-xuan GUO ; Hong MA ; Jun HUANG ; Xin-li LI ; Yun-zhen CHEN
Chinese Journal of Cardiology 2006;34(10):877-881
OBJECTIVETo evaluate the efficacy and safety of olmesartan medoxomil compared with losartan potassium in patients with mild to moderate essential hypertension.
METHODThis is a randomized, double-blind, double-dummy, active-controlled, parallel, multi-center study. After a 2-week placebo run-in period, a total of 287 eligible subjects were randomized at 1:1 ratio to receive olmesartan medoxomil 20 mg or losartan potassium 50 mg, once daily for 8 weeks. The blood pressure was assessed after 4 weeks treatment. If the subject's seating diastolic blood pressure (SeDBP) was still >or=90 mm Hg, the dosage was doubled for another 4 weeks; for those subjects whose SeDBP was <90 mm Hg after 4-week treatment, the initial dosage remained unchanged and the treatment continued until completion of the study.
RESULTS(1) The mean trough reduction in SeDBP from baseline in olmesartan group was significantly greater than that in losartan group after 4 weeks (11.72 mm Hg vs 9.23 mm Hg, P=0.004) and 8 weeks treatment (12.94 mm Hg vs 11.01 mm Hg, P=0.035). (2) The number and percentage of responders in olmesartan group (81, 65.3%) were statistically higher than those (68, 52.7%) in losartan group (P=0.028) after 4 weeks treatment and were similar between the two groups after 8 weeks treatment (P>0.05). (3) Individual and overall trough/peak ratios of DBP and SBP in 24-hour ambulatory blood pressure monitoring were higher in olmesartan group than losartan group. The hypotensive effect of olmesartan was more durable than losartan at 24 hour interval. (4) The incidence of study drug-related adverse events (AEs) in olmesartan group (10.5%) was similar as that in losartan group (13.9%, P>0.05). Most of these AEs were mild and transient.
CONCLUSIONThis study shows that olmesartan medoxomil, at oral dose of 20 mg-40 mg once daily was effective and safe for hypertension treatment and the hypotensive effect was superior to losartan potassium (50 mg-100 mg once daily).
Adolescent ; Adult ; Aged ; Antihypertensive Agents ; administration & dosage ; China ; Double-Blind Method ; Female ; Humans ; Hypertension ; drug therapy ; physiopathology ; Imidazoles ; adverse effects ; therapeutic use ; Losartan ; adverse effects ; therapeutic use ; Male ; Middle Aged ; Olmesartan Medoxomil ; Tetrazoles ; adverse effects ; therapeutic use
4.Clinical study of zoledronic acid in the treatment of cancer-induced hypercalcemia.
Ge SHEN ; San-tai SONG ; Ze-fei JIANG ; Shou-geng BIAN ; Guang-ru XIE ; Ya-jie WANG ; Jie-jun WANG
Chinese Journal of Oncology 2005;27(10):632-634
OBJECTIVETo investigate the effect and safety of zoledronic acid (Zoledex) in patients with cancer-induced hypercalcemia.
METHODSSeventeen patients with cancer-induced hypercalcemia (corrected blood calcium > 2.70 mmol/L) were treated intravenously by 4 mg zoledex within 15 minutes on the first day. The corrected blood calcium was observed every 4 days in the following 28 days.
RESULTSThe response rate was 94.1% (16/17). The mean corrected blood calcium became normal after the first dose of zoledex (P < 0.01). The lowest value was found on the fourteenth day after treatment. The main side effects consisted of fever (29.4%, 5/17), hypocalcemic tetany (11.8%, 2/17) and arythmia (5.9%, 1/17).
CONCLUSIONZoledex is effective and safe in the treatment of patient with cancer-induced hypercalcemia.
Adult ; Aged ; Aged, 80 and over ; Bone Density Conservation Agents ; adverse effects ; therapeutic use ; Diphosphonates ; adverse effects ; therapeutic use ; Female ; Humans ; Hypercalcemia ; drug therapy ; etiology ; Imidazoles ; adverse effects ; therapeutic use ; Male ; Middle Aged ; Neoplasms ; complications ; Safety
5.Cardiovascular safety of vardenafil.
National Journal of Andrology 2004;10(10):790-793
Vardenafil is a new type of PDE5 inhibitor (PDE5I) with great inhibiting potential on PDE5 (IC50: 0.01 nmol/L) for enhancing erectile function. International and domestic clinical studies showed it to be safe and effective in treating ED with mild temporary side effects such as headache, dizziness, flushing and rhinitis. In this paper we reviewed the cardiovascular safety of vardenafil. Studies showed that clinical dosage of vardenafil could decrease the systematic arterial blood pressure mildly (< 10 mmHg) , however, it did not interact in a potentially hazardous way with antihypertensive or antianginal therapy, with the exception of organic nitrates. Vardenafil slightly prolonged the QT interval (QTc) in cardiac repolarization, but with no evidence to prove that it could cause arrhythmia in clinical studies. The rates and categories of cardiovascular adverse events of vardenafil therapy were not significantly different from placebo in 5 clinical trials. Present studies demonstrated that clinical dosage of vardenafil appeared generally well tolerated in most patients with chronic and stable cardiovascular disease and it was an ideal drug for the first line treatment of ED.
Adult
;
Blood Pressure
;
drug effects
;
Erectile Dysfunction
;
drug therapy
;
Heart
;
drug effects
;
Humans
;
Imidazoles
;
adverse effects
;
therapeutic use
;
Male
;
Middle Aged
;
Phosphodiesterase Inhibitors
;
adverse effects
;
therapeutic use
;
Piperazines
;
adverse effects
;
therapeutic use
;
Safety
;
Sulfones
;
adverse effects
;
therapeutic use
;
Triazines
;
adverse effects
;
therapeutic use
;
Vardenafil Dihydrochloride
6.Efficacy and safety of vardenafil in men with erectile dysfunction in general clinical practice.
National Journal of Andrology 2005;11(7):556-559
Since fixed-dose vardenafil clinical trails don't fully represent utilization of phosphodiesterase-5 (PDES) inhibitor in general clinical practice. This article reviews flexible-dose and community practice studies, to assess the efficacy and safety of vardenafil in general clinical practice. The results show that vardenafil improves erectile function in most men treated for ED in clinical practice, and well tolerated.
Adult
;
Aged
;
Community Pharmacy Services
;
Erectile Dysfunction
;
drug therapy
;
Europe
;
Humans
;
Imidazoles
;
adverse effects
;
therapeutic use
;
Male
;
Middle Aged
;
Phosphodiesterase Inhibitors
;
adverse effects
;
therapeutic use
;
Piperazines
;
adverse effects
;
therapeutic use
;
Prospective Studies
;
Sulfones
;
adverse effects
;
therapeutic use
;
Triazines
;
adverse effects
;
therapeutic use
;
Vardenafil Dihydrochloride
7.Reliable efficacy of vardenafil for treatment of erectile dysfunction.
National Journal of Andrology 2006;12(7):666-668
Reliable efficacy is very important to continuing treatment for patients with erectile dysfunction. Vardenafil is a potent, highly selective phosphodiesterase 5 (PDE5) inhibitor. The efficacy and safety of vardenafil has been confirmed in many clinical studies. This paper analyzed the efficacy reliability of vardenafil in clinical trials and real-life practice, concluded that it provided reliable efficacy for key parameters of erection and improved treatment compliance.
Adult
;
Aged
;
Clinical Trials, Phase III as Topic
;
Double-Blind Method
;
Erectile Dysfunction
;
drug therapy
;
Humans
;
Imidazoles
;
adverse effects
;
therapeutic use
;
Male
;
Middle Aged
;
Phosphodiesterase Inhibitors
;
adverse effects
;
therapeutic use
;
Piperazines
;
adverse effects
;
therapeutic use
;
Randomized Controlled Trials as Topic
;
Retrospective Studies
;
Sulfones
;
adverse effects
;
therapeutic use
;
Triazines
;
adverse effects
;
therapeutic use
;
Vardenafil Dihydrochloride
8.Efficacy and safety of vardenafil in the treatment of erectile dysfunction: a report of 700 cases.
Da-Chuan ZHONG ; Xuan-Wen ZHU ; Jia-Jie FANG
National Journal of Andrology 2011;17(12):1092-1096
OBJECTIVETo evaluate the efficacy and safety of long-term on-demand use of vardenafil in the treatment of erectile dysfunction (ED).
METHODSWe conducted a questionnaire investigation among 891 ED patients treated by on-demand use of oral vardenafil at 20 mg every 3 days from March 2007 to January 2010, covering the general information of the patients, their need for and attitudes towards the treatment, clinical efficacy and adverse events of the drug, and satisfaction of the patients and their partners after 12 weeks of treatment.
RESULTSTreatment and follow-up were completed in 700 patients, of whom 504 (72%) achieved sufficient hardness and duration of penile erection and overall sexual satisfaction, 84 (12%) admitted to improvement of erectile hardness and duration but not adequate satisfaction, and the other 112 (16%) experienced no significant changes. Significant differences were found in IIEF-5 scores, Rigiscan test results and partners TSS scores before and after the treatment (P < 0.05). Most frequent adverse events included flushing (15%), dizziness and headache (10%), dyspepsia (3%), and nasal congestion (1%).
CONCLUSIONLong-term on-demand use of oral vardenafil, in addition to its safety and good tolerance, can effectively improve the erectile function of ED patients, their success rate of sexual intercourse, and overall quality of sexual life.
Adult ; Erectile Dysfunction ; drug therapy ; Follow-Up Studies ; Humans ; Imidazoles ; adverse effects ; therapeutic use ; Male ; Piperazines ; adverse effects ; therapeutic use ; Sulfones ; adverse effects ; therapeutic use ; Treatment Outcome ; Triazines ; adverse effects ; therapeutic use ; Vardenafil Dihydrochloride ; Vasodilator Agents ; adverse effects ; therapeutic use ; Young Adult
9.Efficacy and safety of vardenafil in the treatment of erectile dysfunction in men with hypertension.
National Journal of Andrology 2006;12(10):953-956
The prevalence of erectile dysfunction (ED) is higher in hypertension patients than in non-hypertension men. Because doctors worry about the severe adverse events of drug combination, they tend to be reluctant to prescribe ED medicines for patients. Vardenafil, as a novel and highly selective phosphodiesterase 5 inhibitor, has been proved by many clinical trials to be quite safe for the cardiovascular system. A recent large-scale clinical trial showed that vardenafil could improve erectile function in ED men with hypertension, with sure safety and no significant clinical changes in the index of hypertension or heart rate.
Adult
;
Aged
;
Erectile Dysfunction
;
complications
;
drug therapy
;
Humans
;
Hypertension
;
complications
;
Imidazoles
;
adverse effects
;
therapeutic use
;
Male
;
Middle Aged
;
Phosphodiesterase Inhibitors
;
adverse effects
;
therapeutic use
;
Piperazines
;
adverse effects
;
therapeutic use
;
Sulfones
;
adverse effects
;
therapeutic use
;
Treatment Outcome
;
Triazines
;
adverse effects
;
therapeutic use
;
Vardenafil Dihydrochloride
10.Efficacy and tolerability of vardenafil in Asian men with erectile dysfunction.
Hui Meng TAN ; Chong Min CHIN ; Chong Beng CHUA ; Edsal GATCHALIAN ; Apichat KONGKANAND ; Clarence Lei Chang MOH ; Foo Cheong NG ; Krisada RATANA-OLARN ; Dennis SERRANO ; Akmal TAHER ; Ismail TAMBI ; Anupan TANTIWONG ; Michael Wong Yuet CHEN ; Wai-Chun YIP
Asian Journal of Andrology 2008;10(3):495-502
AIMTo evaluate the efficacy and tolerability of vardenafil, a phosphodiesterase type-5 (PDE-5) inhibitor, in men of Asian ethnicity with erectile dysfunction (ED).
METHODSIn this prospective, double-blind, multinational study, Asian men were randomized to receive vardenafil (10 mg) or placebo (4:1 ratio) for 12 weeks. The primary efficacy variables were the International Index of Erectile Function erectile function domain (IIEF-EF), and Sexual Encounter Profile (SEP) questions related to penetration and intercourse completion. Significant mean improvements were required in all three measures to show positive benefits of vardenafil treatment. Secondary efficacy variables included the Global Assessment Question (GAQ) on erection improvement.
RESULTSLeast-squares mean baseline IIEF-EF domain scores (vardenafil 14.6, placebo 13.4) were consistent with moderate ED. After 12 weeks, vardenafil treatment was associated with significant increases from the baseline in IIEF-EF domain scores compared with the placebo (22.4 vs. 14.3; P<0.001). Vardenafil was associated with significant improvements from baseline in least squares (LS) mean success rates for SEP-2 (vardenafil 82.2 vs. placebo 43.6; P<0.001) and SEP-3 (vardenafil 66.1 vs. placebo 24.0; P<0.001). Positive GAQ responses were reported by 81.8% of vardenafil recipients vs. 24.3% of placebo recipients. Adverse events were reported by 25.4% of the vardenafil group, the majority mild and transient.
CONCLUSIONVardenafil (10 mg) is a highly effective and well-tolerated treatment for moderate ED in Asian men. These results add to the increasing amount of data demonstrating the safety and efficacy of vardenafil for the treatment of ED in a range of patient populations.
Adult ; Aged ; Double-Blind Method ; Erectile Dysfunction ; drug therapy ; Humans ; Imidazoles ; adverse effects ; therapeutic use ; Male ; Middle Aged ; Phosphodiesterase Inhibitors ; adverse effects ; therapeutic use ; Piperazines ; adverse effects ; therapeutic use ; Prospective Studies ; Sulfones ; adverse effects ; therapeutic use ; Triazines ; adverse effects ; therapeutic use ; Vardenafil Dihydrochloride